Genenta Science (GNTA) to Release Earnings on Friday

Genenta Science (NASDAQ:GNTA) will likely be posting its results before the market opens on Friday, March 27th. Analysts expect Genenta Science to post earnings of ($0.3641) per share for the quarter.

Genenta Science Stock Performance

GNTA stock opened at $0.72 on Wednesday. The business has a fifty day simple moving average of $0.98 and a 200-day simple moving average of $1.90. Genenta Science has a 52 week low of $0.59 and a 52 week high of $10.00.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Genenta Science presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in Genenta Science during the 3rd quarter worth approximately $41,000. Norges Bank acquired a new stake in Genenta Science in the fourth quarter valued at approximately $337,000. Weiss Asset Management LP acquired a new stake in Genenta Science in the fourth quarter valued at approximately $480,000. Ghisallo Capital Management LLC purchased a new stake in shares of Genenta Science during the fourth quarter valued at approximately $482,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Genenta Science during the fourth quarter worth $328,000. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.